3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Neuroendocrine
1
Carcinoid Tumor
1
Interventions
Paclitaxel
10
trametinib
9
dabrafenib
9
pembrolizumab
5
lenvatinib
5
fosbretabulin
4
Sorafenib
4
Radiotherapy, Intensity-Modulated
4
Doxorubicin
4
Radiotherapy
3
Cisplatin
3
pazopanib
2
efatutazone
2
combretastatin
2
cobimetinib
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Vemurafenib
2
Trastuzumab
2
Taxes
2
Nivolumab
2
Gefitinib
2
Filgrastim
2
Everolimus
2
Docetaxel
2
Carboplatin
2
Bevacizumab
2
zimberelimab
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
zimberelimab
×
Endocrine
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled